A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 1)

Stopped early · Phase 1/Phase 2

Conditions studied: Advanced Solid Tumors

In brief

The purpose of this clinical research study is to study the safety of Epofolate (BMS-753493) in patients with advanced cancers (in Phase 1 portion) and to determine whether Epofolate (BMS-753493) can shrink or slow the growth of the cancer in patients with advanced ovarian, renal or breast cancer (in Phase 2 portion).

Key facts

Study ID

NCT00546247

Run by

Bristol-Myers Squibb

People needed

26

Starts

2008-01-01

Expected to finish

2010-03-01

Last updated by the study team

2015-10-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Advanced cancer, excluding cancer in the blood
• Availability of 10 tumor tissue slides
• Exclusion:
• Known brain metastases
• Severe nerve damage
• Significant cardiovascular disease
• Inadequate blood counts
• Inadequate liver or kidney function
• Inadequate thyroid function or uncontrolled thyroid disease

Where it is running

• Lombardi Comprehensive Cancer Center — Washington D.C., District of Columbia, United States
• Memorial Sloan Kettering Cancer Center — New York, New York, United States
• Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States
• Local Institution — Rotterdam, Netherlands

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.